RAFAEL HLD. news, videos and press releases
For more news please use our advanced search feature.
RAFAEL HLD. - More news...
RAFAEL HLD. - More news...
- Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
- Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
- Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
- Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
- Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
- Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
- Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
- Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
- Rafael Holdings Announces up to $5 Million Share Repurchase Program
- Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
- Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
- Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
- Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
- Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
- Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results
- Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results
- William “Bill” Conkling to assume the role of Chief Executive Officer as of February 1, 2022
- Rafael Holdings Reports First Quarter Fiscal 2022 Financial and Operating Results
- Rafael Holdings Realigns Leadership Team to Support Earlier Stage Pipeline Focus
- Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia
- Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update
